Saito K, Sakai K
Central Research Laboratories, Chugai Pharmaceutical Co, Ltd, Tokyo, Japan.
Fundam Clin Pharmacol. 1998;12(2):143-51. doi: 10.1111/j.1472-8206.1998.tb00934.x.
The effects of nicorandil on systemic blood pressure (SBP) and heart rate (HR) responses to adenosine were compared with those to N6-cyclopentyladenosine (CPA), a selective adenosine A1 receptor agonist, and 5'-(N-cyclopropyl)-carboxamidoadenosine (CPCA), a selective adenosine A2 receptor agonist, in anesthetized rats. When injected intravenously (i.v.), single bolus doses of CPCA (0.01-1.0 micrograms/kg), like adenosine (30 micrograms/kg), elicited dose-dependent decreases in SBP scarcely affecting HR, while CPA (0.03-1.0 micrograms/kg) produced only reduction of HR without influencing SBP. The enhancement of the vasodepressor response to CPCA, like adenosine, was induced by the i.v. infusion of either nicorandil (10 micrograms/kg per min) or cromakalim (0.1 micrograms/kg per min), but the response to CPA in HR remained unmodified during the infusion of nicorandil as well as cromakalim. After i.v. treatment with glibenclamide (20 mg/kg), and adenosine triphosphate (ATP)-sensitive K+ channel blocker, or 3,7-dimethyl-1-propargylxanthine (DMPX) (1 mg/kg), a selective antagonist of adenosine A2 receptor, not only CPCA action but also the enhancement of CPCA action by nicorandil and cromakalim were significantly attenuated. Similar results were obtained in the case of single bolus i.v. adenosine. The present result indicates that the augmentation of the adenosine action by nicorandil appears to be mediated by activation of ATP-sensitive K+ channels, closely linked with stimulation on A2 receptors by adenosine.
在麻醉大鼠中,比较了尼可地尔对腺苷、选择性腺苷A1受体激动剂N6-环戊基腺苷(CPA)和选择性腺苷A2受体激动剂5'-(N-环丙基)-羧酰胺腺苷(CPCA)引起的全身血压(SBP)和心率(HR)反应的影响。静脉注射(i.v.)时,单次推注剂量的CPCA(0.01 - 1.0微克/千克)与腺苷(30微克/千克)一样,引起SBP呈剂量依赖性下降,几乎不影响HR,而CPA(0.03 - 1.0微克/千克)仅使HR降低,不影响SBP。与腺苷一样,静脉输注尼可地尔(10微克/千克/分钟)或克罗卡林(0.1微克/千克/分钟)可诱导对CPCA血管舒张反应的增强,但在输注尼可地尔和克罗卡林期间,对CPA的HR反应保持不变。在用格列本脲(20毫克/千克)(一种ATP敏感性钾通道阻滞剂)或3,7-二甲基-1-炔丙基黄嘌呤(DMPX)(1毫克/千克)(一种腺苷A2受体选择性拮抗剂)进行静脉治疗后,不仅CPCA的作用,而且尼可地尔和克罗卡林对CPCA作用的增强均显著减弱。单次静脉推注腺苷时也获得了类似结果。目前的结果表明,尼可地尔对腺苷作用的增强似乎是由ATP敏感性钾通道的激活介导的,这与腺苷对A2受体的刺激密切相关。